Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Shaughnessy

Showing results (41-50 of 53) with videos related to

Pageof 6
Sort By:
Cancer Research|December 26, 2003
High heparanase activity in multiple myeloma is associated with elevated microvessel densityThomas Kelly, Hua-Quan Miao, Yang Yang, et al.
Blood|April 24, 2004
RHAMM expression and isoform balance predict aggressive disease and poor survival in multiple myelomaChristopher A Maxwell, Erik Rasmussen, Fenghuang Zhan, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 1, 2007
Immunization with a recombinant MAGE-A3 protein after high-dose therapy for myelomaSusann Szmania, Sacha Gnjatic, Guido Tricot, et al.
International Journal of Cancer|August 12, 2004
Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapyAlessandro D Santin, Fenghuang Zhan, Stefania Bellone, et al.
Blood Advances|January 9, 2025
Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myelomaSamer Al Hadidi, Obada Ababneh, Carolina Schinke, et al.
The New England Journal of Medicine|March 10, 2006
Thalidomide and hematopoietic-cell transplantation for multiple myelomaBart Barlogie, Guido Tricot, Elias Anaissie, et al.
Blood|February 28, 2002
Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cellsFenghuang Zhan, Johanna Hardin, Bob Kordsmeier, et al.
Blood|January 18, 2003
Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expressionJohn Shaughnessy, Joth Jacobson, Jeff Sawyer, et al.
Virology|January 5, 2005
Gene expression profiles of primary HPV16- and HPV18-infected early stage cervical cancers and normal cervical epithelium: identification of novel candidate molecular markers for cervical cancer diagnosis and therapyAlessandro D Santin, Fenghuang Zhan, Eliana Bignotti, et al.
Current Research in Translational Medicine|April 24, 2021
PHF19 inhibition as a therapeutic target in multiple myelomaCarolina D Schinke, Jordan T Bird, Pingping Qu, et al.
Pageof 6

Showing results (41-50 of 53) with videos related to

Sort By:
Pageof 6
Cancer Research|December 26, 2003
High heparanase activity in multiple myeloma is associated with elevated microvessel densityThomas Kelly, Hua-Quan Miao, Yang Yang, et al.
Blood|April 24, 2004
RHAMM expression and isoform balance predict aggressive disease and poor survival in multiple myelomaChristopher A Maxwell, Erik Rasmussen, Fenghuang Zhan, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 1, 2007
Immunization with a recombinant MAGE-A3 protein after high-dose therapy for myelomaSusann Szmania, Sacha Gnjatic, Guido Tricot, et al.
International Journal of Cancer|August 12, 2004
Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapyAlessandro D Santin, Fenghuang Zhan, Stefania Bellone, et al.
Blood Advances|January 9, 2025
Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myelomaSamer Al Hadidi, Obada Ababneh, Carolina Schinke, et al.
The New England Journal of Medicine|March 10, 2006
Thalidomide and hematopoietic-cell transplantation for multiple myelomaBart Barlogie, Guido Tricot, Elias Anaissie, et al.
Blood|February 28, 2002
Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cellsFenghuang Zhan, Johanna Hardin, Bob Kordsmeier, et al.
Blood|January 18, 2003
Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expressionJohn Shaughnessy, Joth Jacobson, Jeff Sawyer, et al.
Virology|January 5, 2005
Gene expression profiles of primary HPV16- and HPV18-infected early stage cervical cancers and normal cervical epithelium: identification of novel candidate molecular markers for cervical cancer diagnosis and therapyAlessandro D Santin, Fenghuang Zhan, Eliana Bignotti, et al.
Current Research in Translational Medicine|April 24, 2021
PHF19 inhibition as a therapeutic target in multiple myelomaCarolina D Schinke, Jordan T Bird, Pingping Qu, et al.
Pageof 6